Drugs / JadiCell™
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07479043 | Jul → Dec 2026 expected | acute respiratory distress syndrome | Breathe Biologics, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JadiCell | “JadiCell™, an investigational umbilical cord-derived mesenchymal stem cell therapy, in patients diagnosed with Acute Respiratory Distress Syndrome (ARDS).” NCT07479043 ↗ |
| Known as | JadiCells | “JadiCells are administered intravenously and are intended to modulate inflammatory responses and promote tissue repair in injured lung tissue.” NCT07479043 ↗ |
| Modality | Cell therapy | “umbilical cord-derived mesenchymal stem cell therapy” NCT07479043 ↗ |
| Route | Intravenous | “JadiCells are administered intravenously” NCT07479043 ↗ |